<DOC>
	<DOC>NCT00423501</DOC>
	<brief_summary>This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or 20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is &lt;3 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes mellitus, with stable metformin treatment for &gt;=3 months; stable weight +/10% for &gt;=3 months before screening. type 1 diabetes mellitus; treatment with any antihyperglycemic medication other than metformin monotherapy during last 3 months; use of weightlowering medications in the last 3 months; uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>